• Western blot analysis of extracts of various cell lines, using PLG antibody (STJ25027) at 1:1000 dilution. Secondary antibody: HRP Goat Anti-Rabbit IgG (H+L) (STJS000856) at 1:10000 dilution. Lysates/proteins: 25 Mu g per lane. Blocking buffer: 3% nonfat dry milk in TBST. Detection: ECL Basic Kit. Exposure time: 1s.

Anti-PLG antibody (20-300) (STJ25027)

SKU:
STJ25027

Shipping:
Free Shipping
Current Stock:
Host: Rabbit
Applications: WB
Reactivity: Human/Mouse/Rat
Note: STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS.
Short Description: Rabbit polyclonal antibody anti-PLG (20-300) is suitable for use in Western Blot research applications.
Clonality: Polyclonal
Conjugation: Unconjugated
Isotype: IgG
Formulation: PBS with 0.02% Sodium Azide, 50% Glycerol, pH7.3.
Purification: Affinity purification
Dilution Range: WB 1:500-1:2000
Storage Instruction: Store at-20°C for up to 1 year from the date of receipt, and avoid repeat freeze-thaw cycles.
Gene Symbol: PLG
Gene ID: 5340
Uniprot ID: PLMN_HUMAN
Immunogen Region: 20-300
Immunogen: Recombinant fusion protein containing a sequence corresponding to amino acids 20-300 of human PLG (NP_000292.1).
Immunogen Sequence: EPLDDYVNTQGASLFSVTKK QLGAGSIEECAAKCEEDEEF TCRAFQYHSKEQQCVIMAEN RKSSIIIRMRDVVLFEKKVY LSECKTGNGKNYRGTMSKTK NGITCQKWSSTSPHRPRFSP ATHPSEGLEENYCRNPDNDP QGPWCYTTDPEKRYDYCDIL ECEEECMHCSGENYDGKISK TMSGLECQAWDSQSPHAHGY IPSKFPNKNLKKNYCRNPDR ELRPWCFTTDPNKRWELCD
Tissue Specificity Present in plasma and many other extracellular fluids. It is synthesized in the liver.
Post Translational Modifications N-linked glycan contains N-acetyllactosamine and sialic acid. O-linked glycans consist of Gal-GalNAc disaccharide modified with up to 2 sialic acid residues (microheterogeneity). In the presence of the inhibitor, the activation involves only cleavage after Arg-580, yielding two chains held together by two disulfide bonds. In the absence of the inhibitor, the activation involves additionally the removal of the activation peptide.
Function Plasmin dissolves the fibrin of blood clots and acts as a proteolytic factor in a variety of other processes including embryonic development, tissue remodeling, tumor invasion, and inflammation. In ovulation, weakens the walls of the Graafian follicle. It activates the urokinase-type plasminogen activator, collagenases and several complement zymogens, such as C1 and C5. Cleavage of fibronectin and laminin leads to cell detachment and apoptosis. Also cleaves fibrin, thrombospondin and von Willebrand factor. Its role in tissue remodeling and tumor invasion may be modulated by CSPG4. Binds to cells. Angiostatin is an angiogenesis inhibitor that blocks neovascularization and growth of experimental primary and metastatic tumors in vivo. (Microbial infection) ENO/enoloase from parasite P.falciparum (strain NF54) interacts with PLG present in the mosquito blood meal to promote the invasion of the mosquito midgut by the parasite ookinete. The catalytic active form, plasmin, is essential for the invasion of the mosquito midgut. (Microbial infection) Binds to OspC on the surface of B.burgdorferi cells, possibly conferring an extracellular protease activity on the bacteria that allows it to traverse host tissue.
Protein Name Plasminogen Cleaved Into - Plasmin Heavy Chain A - Activation Peptide - Angiostatin - Plasmin Heavy Chain A - Short Form - Plasmin Light Chain B
Database Links Reactome: R-HSA-114608
Reactome: R-HSA-1474228
Reactome: R-HSA-1592389
Reactome: R-HSA-186797
Reactome: R-HSA-381426
Reactome: R-HSA-75205
Cellular Localisation Secreted
Locates To The Cell Surface Where It Is Proteolytically Cleaved To Produce The Active Plasmin
Interaction With Hrg Tethers It To The Cell Surface
Alternative Antibody Names Anti-Plasminogen Cleaved Into - Plasmin Heavy Chain A - Activation Peptide - Angiostatin - Plasmin Heavy Chain A - Short Form - Plasmin Light Chain B antibody
Anti-PLG antibody

Information sourced from Uniprot.org

12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance